-
公开(公告)号：US20240115492A1
公开(公告)日：2024-04-11
申请号：US18262867
申请日：2022-01-28
发明人： María Carmen LLUCH LORES , Xavier FORMOSA MÁRQUEZ , Almudena DOMÍNGUEZ FERNÁNDEZ , Diego TORREA GOÑI
IPC分类号： A61K9/00 , A61K9/20 , A61K31/135 , A61K31/137
CPC分类号： A61K9/0056 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K31/135 , A61K31/137
摘要： The present invention relates to an orodispersible pharmaceutical solid dosage form comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof a pharmaceutically acceptable polymer suitable for forming a matrix with rasagiline or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, wherein rasagiline or a pharmaceutically acceptable salt thereof is trapped within the matrix, and wherein said dosage form exhibits a dissolution profile according to which (i) after 2 minutes at pH=7.0, less than 12% w/w of the rasagiline relative to the total rasagiline content of the dosage form is dissolved, and (ii) after 15 minutes at pH=1.2, more than 75% w/w of the rasagiline relative to the total rasagiline content of the dosage form is dissolved, and (iii) after 40 minutes at pH=1.2, at least 90% w/w of the rasagiline relative to the total rasagiline content of the dosage form is dissolved, and wherein said orodispersible pharmaceutical solid dosage form is disintegrated in less than 3 minutes.
-
公开(公告)号：US20220265688A1
公开(公告)日：2022-08-25
申请号：US17625649
申请日：2020-07-09
IPC分类号： A61K31/675 , A61K47/26 , A61K9/00
摘要： A stable oral composition for cyclophosphamide or its pharmaceutically acceptable salt. The composition for cyclophosphamide can be in the form of powder for oral solution, which can provide an improved stability, ease for reconstitution, and better palatability suitable for pediatric patients. Also disclosed is a process for preparation of the powder for oral solution of cyclophosphamide.
-
公开(公告)号：US20220153743A1
公开(公告)日：2022-05-19
申请号：US17435605
申请日：2020-03-04
发明人： Rama SHANKAR , Pareshkumar Keshavlal PATEL , Dhavalkumar Bharatbhai VASHI , Ranjitkumar Ravatbhai PADA , Ganesh Bhanudas DHEPE , Viralkumar Arvindbhai DOSHI , Jaydip Ghanshyambhai RAJPARA
IPC分类号： C07D487/04
摘要： The present invention relates to an improved process for preparation of tofacitinib (I) and pharmaceutically acceptable salt thereof. (I)
-
公开(公告)号：US20210100821A1
公开(公告)日：2021-04-08
申请号：US16971179
申请日：2019-02-26
发明人： Aditya PATEL , Kerul PATEL , Dhaval DADHANIYA
IPC分类号： A61K31/675 , A61K9/19 , A61K47/26
摘要： This present invention relates to a stable lyophilized composition of Cyclophosphamide. The said stable lyophilized composition of Cyclophosphamide provides an improved moisture content than the lyophilized Cyclophosphamide compositions obtained by the conventional lyophilization method. Further, the invention relates to a process for preparation of the said stable lyophilized composition of Cyclophosphamide, wherein the said process comprises controlled lyophilization with freezing and annealing at a temperature above 0° C.
-
公开(公告)号：US20200054573A1
公开(公告)日：2020-02-20
申请号：US16334115
申请日：2017-09-16
发明人： Mayank SAXENA , Rikin PATEL , Piyush KANSAGRA , Balvir SINGH , Ashish SEHGAL
IPC分类号： A61K9/50 , A61K31/5513 , A61K9/51 , A61K9/20
摘要： An extended release pharmaceutical composition of Clozapine The extended release composition of Clozapine provides an extended release pharmaceutical composition having Clozapine, a seal coating, an acidic coating, and an extended release coating. The composition is particularly suitable for dispensing a once-a-day solid oral pharmaceutical formulation which releases a therapeutically effective amount of Clozapine over an extended time period.
-
公开(公告)号：US20170112901A1
公开(公告)日：2017-04-27
申请号：US15300504
申请日：2015-02-27
CPC分类号： A61K38/1816 , A61K9/0019 , A61K9/08 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/26 , A61K47/60 , C07K1/107 , C07K14/505
摘要： A liquid pharmaceutical composition having a conjugated erythropoietin, buffer, sugar, tonicity modifier and amino acid as an aggregation inhibitor. The liquid pharmaceutical composition provides a stable pharmaceutical composition which encompasses conjugated erythropoietin, acetate buffer, sucrose, arginine and sodium chloride which is maintained at a pH of about 4.9 to 5.3.
-
公开(公告)号：US11833253B1
公开(公告)日：2023-12-05
申请号：US17967244
申请日：2022-10-17
发明人： Mayank Saxena , Rikin Patel , Piyush Kansagra , Balvir Singh , Ashish Sehgal
IPC分类号： A61K9/50 , A61K9/20 , A61K9/51 , A61K31/5513 , A61K9/00 , A61K9/48 , A61K47/10 , A61K47/12 , A61K47/38
CPC分类号： A61K9/5073 , A61K9/2077 , A61K9/5015 , A61K9/5047 , A61K9/5192 , A61K31/5513
摘要： An extended release pharmaceutical composition of Clozapine The extended release composition of Clozapine provides an extended release pharmaceutical composition having Clozapine, a seal coating, an acidic coating, and an extended release coating. The composition is particularly suitable for dispensing a once-a-day solid oral pharmaceutical formulation which releases a therapeutically effective amount of Clozapine over an extended time period.
-
公开(公告)号：US20220273652A1
公开(公告)日：2022-09-01
申请号：US17631676
申请日：2020-07-30
发明人： Hitendra Netlal RAHANGDALE , Narendra Bhagwatbhai PRAJAPATI , Satyavan Shivajirao DHAVALE , Venkataramana NAIDU
IPC分类号： A61K31/505 , A61K31/216 , A61K9/24 , A61K9/20
摘要： A multilayer, pharmaceutical composition having a fixed dose combination of rosuvastatin or a pharmaceutically acceptable salt thereof and fenofibrate or a pharmaceutically acceptable salt thereof, wherein the fenofibrate or the pharmaceutically acceptable salt thereof and the rosuvastatin or the pharmaceutically acceptable salt thereof are present in separate layers, namely a fenofibrate layer and a rosuvastatin layer, wherein fenofibrate and rosuvastatin are immediately released from the fenofibrate layer and the rosuvastatin layer, respectively, and wherein the fenofibrate layer having micronized fenofibrate. A process for the preparation of the composition is also disclosed.
-
公开(公告)号：US20220211709A1
公开(公告)日：2022-07-07
申请号：US17605796
申请日：2020-04-30
发明人： Anil NAYANI , Mukesh BOTHRA , Alex GEORGE
IPC分类号： A61K31/519 , A61K9/00 , A61P35/00
摘要： The present invention provides a stable, ready to use aqueous parenteral composition comprising Pemetrexed, wherein the composition comprises Pemetrexed disodium, mixture of antioxidants and pharmaceutically acceptable excipients. Further the present invention provides process for preparation of said composition.
-
公开(公告)号：US10688187B2
公开(公告)日：2020-06-23
申请号：US15301421
申请日：2015-02-18
摘要： A liquid pharmaceutical composition having an anti-TNFα antibody, a buffer, a stabilizer, and a surfactant.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.016 秒)
